Myeloproliferative disorder with eosinophilia and ETV6–ABL gene rearrangement: Efficacy of second-generation tyrosine kinase inhibitors
- 31 August 2009
- journal article
- case report
- Published by Elsevier BV in Leukemia Research
- Vol. 33 (8), 1144-1146
- https://doi.org/10.1016/j.leukres.2009.03.011
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithmsLeukemia, 2007
- Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disordersBlood, 2006
- Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusionCancer Genetics and Cytogenetics, 2005
- Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangementCancer Genetics and Cytogenetics, 2002
- Molecular cytogenetic and clinical findings inETV6/ABL1-positive leukemiaGenes, Chromosomes and Cancer, 2000
- Late Appearance of t(5;12)(q31;p12) in Acute Myeloid Leukemia Associated with EosinophiliaCancer Genetics and Cytogenetics, 1998
- ETV6/ABL fusion is rare in Ph-negative chronic myeloid disordersLeukemia, 1998
- BCR/ABL-negative chronic myeloid leukemia withETV6/ABL fusionGenes, Chromosomes and Cancer, 1997
- Oligomerization of the ABL Tyrosine Kinase by the Ets Protein TEL in Human LeukemiaMolecular and Cellular Biology, 1996
- Abnormalities of chromosome 12p 13 and malignant proliferation of eosinophils: a nonrandom associationBritish Journal of Haematology, 1987